Icaritin

淫羊藿素

Report date: 2023/01/13 11:03:59
NMEFirst In Class

Base Information

Drug NameIcaritin
Drug Alias Name去水淫羊藿黄素淫羊藿素淫羊藿苷元淫羊藿黄素淫羊霍苷 +[9] 
ClassificationNatural product/Extract > Plants extract
Mechanisms of ActionMyeloid differentiation primary response protein MyD88 inhibitorsImmunomodulatorsInhibitor of nuclear factor kappa-B kinase subunit alpha inhibitors +[5] 
TargetsMyeloid differentiation primary response protein MyD88Inhibitor of nuclear factor kappa-B kinase subunit alphaEstrogen receptor alpha +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsCarcinoma, Hepatocellular
Approved Indications in ChinaCarcinoma, Hepatocellular
Original Approved Country/TerritoryMainland China
Original Approved Date2022/01/10
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenogen Pharma Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Shen Nuojii Pharmaceutical Technology Co Ltd
Inactive CompaniesBeijing Kang'Erfu Pharmaceutical Co LtdShenogen Pharma Group LtdBeijing Shenogen Biomedical Co Ltd
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsMetastatic breast cancerSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A